News
Stocktwits on MSN38m
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay OptimisticRetail chatter around GSK picked up on Thursday after Blenrep, one of its cancer drugs, hit a roadblock with U.S. regulators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback